DMRA
NASDAQ HealthcareDamora Therapeutics, Inc. - Common Stock
Biotechnology
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
๐ Market Data
| Price | $25.36 |
|---|---|
| Volume | 220,960 |
| Market Cap | 1.53B |
| Beta | 1.600 |
| RSI (14-Day) | 43.5 |
| 200-Day MA | $17.12 |
| 50-Day MA | $26.14 |
| 52-Week High | $38.33 |
| 52-Week Low | $2.45 |
| Forward P/E | -10.39 |
| Price / Book | -0.23 |
๐ฏ Investment Strategy Scores
DMRA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (89/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find DMRA in your text
Paste any article, transcript, or post โ the tool will extract DMRA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.